HDL in humans with cardiovascular disease exhibits a proteomic signature

Clinica Chimica Acta

Volumn 411, Issue 13-14, 2010, Pages 972-979

  Vaisar, Tomáš ^a   Mayer, Philip ^a   Nilsson, Erik ^b   Zhao, Xue Qiao ^a   Knopp, Robert ^a   Prazen, Bryan J ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Insilicos   (United States)

Author keywords

Cardiovascular risk score; Inflammation; Mass spectrometry; Oxidized HDL; Partial least squares discriminant analysis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; METHIONINE; TRYPSIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE MARKER; HUMAN; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATTERN RECOGNITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ISOLATION; PROTEIN METABOLISM; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; TANDEM MASS SPECTROMETRY;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PATTERN RECOGNITION, AUTOMATED; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 77952543789     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.03.023     Document Type: Article

References (45)

1. Movva R., Rader D.J. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008, 54:788-800.
2. Khovidhunkit W., Kim M.S., Memon R.A., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169-1196.
3. Van Lenten B., Hama S., de Beer F., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995, 96:2758-2767.
4. Getz G.S., Reardon C.A. SAA, HDL biogenesis, and inflammation. J Lipid Res 2008, 49:269-270.
5. Vaisar T., Pennathur S., Green P.S., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007, 117:746-756.
6. Tall A.R. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 2008, 263:256-273.
7. Oram J.F., Heinecke J.W. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 2005, 85:1343-1372.
8. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
9. Laberge M.A., Moore K.J., Freeman M.W. Atherosclerosis and innate immune signaling. Ann Med 2005, 37:130-140.
10. Rader D.J. Illuminating HDL-is it still a viable therapeutic target?. N Engl J Med 2007, 357:2180-2183.
11. Warden C.H., Hedrick C.C., Qiao J.H., Castellani L.W., Lusis A.J. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 1993, 261:469-472.
12. Bergt C., Pennathur S., Fu X., et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004, 101:13,032-13,037.
13. Shao B., Cavigiolio G., Brot N., Oda M.N., Heinecke J.W. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci 2008, 105:12,224-12,229.
14. Shao B., Bergt C., Fu X., et al. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J Biol Chem 2005, 280:5983-5993.
15. Panzenböck U., Stocker R. Formation of methionine sulfoxide-containing specific forms of oxidized high-density lipoproteins. Biochim Biophys Acta (BBA) - Proteins Proteomics 2005, 1703:171-181.
16. Zheng L., Nukuna B., Brennan M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004, 114:529-541.
17. Francis G.A. High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta 2000, 1483:217-235.
18. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Fogelman A.M. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2006, 2:504-511.
19. Levels J.H.M., Pajkrt D., Schultz M., et al. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta (BBA) - Mol Cell Biol Lipids 2007, 1771:1429-1438.
20. Villanueva J., Philip J., Chaparro C.A., et al. Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 2005, 4:1060-1072.
21. Gillette M.A., Mani D.R., Carr S.A. Place of pattern in proteomic biomarker discovery. J Proteome Res 2005, 4:1143-1154.
22. Villanueva J., Shaffer D.R., Philip J., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006, 116:271-284.
23. Barker M., Rayens W. Partial least squares for discrimination. J Chemometr 2003, 16:166-173.
24. Lee K.R., Lin X., Park D.C., Eslava S. Megavariate data analysis of mass spectrometric proteomics data using latent variable projection method. Proteomics 2003, 3:1680-1686.
25. Szajli E., Feher T., Medzihradszky K.F. Investigating the quantitative nature of MALDI-TOF MS. Mol Cell Proteomics 2008, 7:2410-2418.
26. Smit S., van Breemen M.J., Hoefsloot H.C.J., Smilde A.K., Aerts J.M.F.G., de Koster C.G. Assessing the statistical validity of proteomics based biomarkers. Anal Chim Acta 2007, 592:210-217.
27. Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett 2006, 27:861-874.
28. Callesen A.K., Madsen J.S., Vach W., Kruse T.A., Mogensen O., Jensen O.N. Serum protein profiling by solid phase extraction and mass spectrometry: a future diagnostics tool?. Proteomics 2009, 9:1428-1441.
29. Michaud F.T., Garnier A., Lemieux L., Duchesne C. Multivariate analysis of single quadrupole LC-MS spectra for routine characterization and quantification of intact proteins. Proteomics 2009, 9:512-520.
30. Somorjai R.L., Dolenko B., Baumgartner R. Class prediction and discovery using gene microarray and proteomics mass spectroscopy data: curses, caveats, cautions. Bioinformatics 2003, 19:1484-1491.
31. Hendriks M.M., Smit S., Akkermans W.L., et al. How to distinguish healthy from diseased? Classification strategy for mass spectrometry-based clinical proteomics. Proteomics 2007, 7:3672-3680.
32. Heidema A.G., Thissen U., Boer J.M., Bouwman F.G., Feskens E.J., Mariman E.C. The association of 83 plasma proteins with CHD mortality, BMI, HDL-, and total-cholesterol in men: applying multivariate statistics to identify proteins with prognostic value and biological relevance. J Proteome Res 2009, 8:2640-2649.
33. Suk Danik J., Rifai N., Buring J.E., Ridker P.M. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006, 296:1363-1370.
34. Ooi E.M., Barrett P.H., Chan D.C., Watts G.F. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008, 114:611-624.
35. Shachter N.S. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001, 12:297-304.
36. Roberts L.M., Ray M.J., Shih T.W., Hayden E., Reader M.M., Brouillette C.G. Structural analysis of apolipoprotein A-I: limited proteolysis of methionine-reduced and -oxidized lipid-free and lipid-bound human apo A-I. Biochemistry 1997, 36:7615-7624.
37. Shao B., Oda M.N., Oram J.F., Heinecke J.W. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006, 21:322-328.
38. Brock J.W., Jenkins A.J., Lyons T.J., et al. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res 2008, 49:847-855.
39. Stapels M.D., Barofsky D.F. Complementary use of MALDI and ESI for the HPLC-MS/MS analysis of DNA-binding proteins. Anal Chem 2004, 76:5423-5430.
40. Martens H., Naes T. Multivariate calibration 1989, John Wiley & Sons, New York.
41. Lloyd-Jones D.M., Liu K., Tian L., Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 2006, 145:35-42.
42. Anderson N.L. The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol Cell Proteomics 2005, 4:1441-1444.
43. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
44. Walldius G., Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Intern Med 2006, 259:493-519.
45. Walldius G., Jungner I. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol 2007, 22:359-367.